Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998–2006: factors associated with improved survival outcome

References

• Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962–2972.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787–2793.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113:209–216.
   PubMed Web of Science ®Google Scholar
• Reynolds C, Ratanatharathorn V, Adams P, et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001;27:801–807.
   PubMedGoogle Scholar
• Mohty M, Boiron JM, Damaj G, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:77–84.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362–4364.
   PubMed Web of Science ®Google Scholar
• Ballen KK, King R, Carston M, et al. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant 2005;35:675–681.
   PubMed Web of Science ®Google Scholar
• Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–3594.
   PubMed Web of Science ®Google Scholar
• Georges GE, Maris MB, Maloney DG, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423–432.
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105: 4532–4539.
   PubMed Web of Science ®Google Scholar
• Lee C-K, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003;31:73–80.
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574–2579.
   PubMed Web of Science ®Google Scholar
• Majolino I, Davoli M, Carnevalli E, et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007;48:759–766.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41:953–960.
   PubMed Web of Science ®Google Scholar
• Nivison-Smith I, Bradstock KF, Dodds AJ, et al. Hematopoietic stem cell transplantation in Australia and New Zealand,1992-2004.. Biol Blood Marrow Transplant 2007; 13:905–912.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825–828.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:177–179.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma:the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375–3382.
   PubMed Web of Science ®Google Scholar
• Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009;113:3383–3391.
   PubMed Web of Science ®Google Scholar
• Efebera YA, Qureshi SR, Cole SM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010;16: 1122–1129.
   PubMed Web of Science ®Google Scholar
• Majolino I, Corradini P, Scimè R, et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant 2003;31:767–773.
   PubMed Web of Science ®Google Scholar
• Kröger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010;148:323–331.
   PubMed Web of Science ®Google Scholar
• Kumar S, Shrestha S, Zhang M-J, et al. Allogeneic stem cell transplantation (SCT) for multiple myeloma (MM) – what has changed? A CIBMTR analysis from 1989–2005. Blood 2009;114(Suppl. 1): Abstract 54.
   Google Scholar
• Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010;28:4521–4530.
   PubMed Web of Science ®Google Scholar